MX361680B - Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso. - Google Patents

Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.

Info

Publication number
MX361680B
MX361680B MX2015007447A MX2015007447A MX361680B MX 361680 B MX361680 B MX 361680B MX 2015007447 A MX2015007447 A MX 2015007447A MX 2015007447 A MX2015007447 A MX 2015007447A MX 361680 B MX361680 B MX 361680B
Authority
MX
Mexico
Prior art keywords
cyclic purine
present
cyclic
compositions
preparation
Prior art date
Application number
MX2015007447A
Other languages
English (en)
Spanish (es)
Other versions
MX2015007447A (es
Inventor
W Dubensky Thomas Jr
B Kanne David
Lai Ling Leong Meredith
Emile Lemmens Edward
Hix Glickman Laura
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of MX2015007447A publication Critical patent/MX2015007447A/es
Publication of MX361680B publication Critical patent/MX361680B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2015007447A 2012-12-13 2013-12-13 Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso. MX361680B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737006P 2012-12-13 2012-12-13
US201361790514P 2013-03-15 2013-03-15
PCT/US2013/075189 WO2014093936A1 (en) 2012-12-13 2013-12-13 Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use

Publications (2)

Publication Number Publication Date
MX2015007447A MX2015007447A (es) 2015-12-09
MX361680B true MX361680B (es) 2018-12-13

Family

ID=50935019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007447A MX361680B (es) 2012-12-13 2013-12-13 Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.

Country Status (18)

Country Link
US (2) US9695212B2 (enExample)
EP (2) EP3527579A1 (enExample)
JP (2) JP6333843B2 (enExample)
KR (1) KR20150095668A (enExample)
CN (2) CN108542913A (enExample)
AU (2) AU2013358892B2 (enExample)
BR (1) BR112015013440B1 (enExample)
CA (1) CA2886456A1 (enExample)
DK (1) DK2931738T3 (enExample)
EA (1) EA201590396A1 (enExample)
ES (1) ES2718910T3 (enExample)
HU (1) HUE043262T2 (enExample)
MX (1) MX361680B (enExample)
PL (1) PL2931738T3 (enExample)
PT (1) PT2931738T (enExample)
SG (2) SG10201704611WA (enExample)
SI (1) SI2931738T1 (enExample)
WO (1) WO2014093936A1 (enExample)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
SG11201407875UA (en) * 2012-06-08 2014-12-30 Aduro Biotech Compostions and methods for cancer immunotherapy
SG10201704611WA (en) 2012-12-13 2017-07-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
PT2934598T (pt) 2012-12-19 2018-07-24 Univ Texas Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero
MX374828B (es) 2013-04-29 2025-03-06 Memorial Sloan Kettering Cancer Center Composiciones y metodos para alterar la señalizacion del segundo mensajero.
US20140329889A1 (en) * 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
CN105188373B (zh) * 2013-05-18 2017-09-22 艾杜罗生物科技公司 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP2996473B1 (en) 2013-05-18 2019-08-21 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3071209A4 (en) * 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
CN103908468B (zh) * 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
AU2015270640B2 (en) 2014-06-04 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
JP6762030B2 (ja) * 2014-11-20 2020-09-30 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
US10011630B2 (en) 2014-12-16 2018-07-03 Invivogen Cyclic dinucleotides for cytokine induction
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
SG11201806623VA (en) 2015-02-11 2018-09-27 Univ Johns Hopkins Bacteria over-expressing c-di-amp and therapeutic methods
JP6692826B2 (ja) * 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
EP3666282A1 (en) 2015-06-03 2020-06-17 The Medical College of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
KR102434314B1 (ko) 2015-09-01 2022-08-19 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
CN105367617A (zh) * 2015-09-25 2016-03-02 武汉品生科技有限公司 一种基于环二腺核苷酸的衍生物、tat多肽及其在一型干扰素小分子中抑制剂的应用
WO2017075477A1 (en) * 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
CN106539813B (zh) * 2015-11-30 2019-12-03 杭州星鳌生物科技有限公司 干扰素刺激基因(sting)激活剂在抗炎症中的应用
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
CN106554416B (zh) * 2015-12-09 2019-03-15 聊城市奥润生物医药科技有限公司 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白（sting）激动剂在抗肿瘤中的应用
CN106540260A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用
CN106539814A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗类风湿性关节炎等疾病中的应用
WO2017106740A1 (en) * 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
EP3402801B1 (en) 2016-01-11 2025-08-06 Innate Tumor Immunity, Inc. Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
CN109069440A (zh) * 2016-03-02 2018-12-21 得克萨斯州大学系统董事会 用于免疫治疗的激活sting的纳米疫苗
MA43827A (fr) 2016-03-18 2018-11-28 Immune Sensor Llc Composés di-nucléotides cycliques et leurs procédés d'utilisation
CN106539757A (zh) * 2016-03-20 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
EP3448393A1 (en) 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN109843302B (zh) 2016-07-06 2022-11-29 F-星治疗公司 用于治疗疾病的化合物、组合物和方法
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018026884A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
US11052149B2 (en) 2016-09-19 2021-07-06 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
SG10202008647TA (en) 2016-10-04 2020-10-29 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
US11001605B2 (en) 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018106864A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
WO2018119117A1 (en) * 2016-12-22 2018-06-28 The Regents Of The University Of California Methods of producing cyclic dinucleotides
JP2018131427A (ja) * 2017-02-17 2018-08-23 国立研究開発法人理化学研究所 免疫細胞の制御技術
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
JP7591348B2 (ja) 2017-02-21 2024-11-28 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
CN106928298B (zh) * 2017-03-13 2021-10-22 杭州星鳌生物科技有限公司 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2018208667A1 (en) 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2018232217A1 (en) 2017-06-16 2018-12-20 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment of cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
TWI808092B (zh) 2017-08-30 2023-07-11 中國大陸商北京軒義醫藥科技有限公司 作為干擾素基因調節劑之刺激劑的環狀二核苷酸
US11638716B2 (en) 2017-08-31 2023-05-02 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
EP3692034A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
EP3694532B1 (en) 2017-10-10 2025-02-26 Gritstone bio, Inc. Neoantigen identification using hotspots
MX2020004858A (es) 2017-11-10 2020-10-01 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso.
CN111936136B (zh) 2017-11-14 2024-07-05 儿童医学中心公司 新咪唑并嘧啶化合物及其用途
KR102775718B1 (ko) 2017-11-14 2025-03-06 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing junction epitope presentation for neoantigens
KR102492115B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
CA3084569A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US12065649B2 (en) 2018-01-09 2024-08-20 Vanderbilt University Pattern recognition receptor agonist prodrugs and methods of use thereof
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
WO2019161171A1 (en) * 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists
WO2019183578A1 (en) 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
EP3774834A1 (en) 2018-03-27 2021-02-17 Boehringer Ingelheim International GmbH Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
CN111989338A (zh) 2018-03-27 2020-11-24 勃林格殷格翰国际有限公司 修饰的环二核苷酸化合物
TWI793294B (zh) 2018-04-03 2023-02-21 美商默沙東有限責任公司 Sting促效劑化合物
EP3774765A4 (en) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
MA52754A (fr) 2018-05-25 2021-04-14 Incyte Corp Composés hétérocycliques tricycliques en tant qu'activateurs de sting
JP7335277B2 (ja) 2018-06-01 2023-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 膀胱がんの治療のための方法
CA3106110A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
CA3107263A1 (en) * 2018-08-03 2020-02-06 The University Of Tokyo Nasal vaccine that induces cell-mediated immunity
TWI717804B (zh) 2018-08-16 2021-02-01 日商衛材R&D企管股份有限公司 化合物之鹽及其晶體
WO2020041720A1 (en) 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
AU2019337051B2 (en) 2018-09-06 2023-11-23 Daiichi Sankyo Company, Limited Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
CN112770771A (zh) * 2018-09-17 2021-05-07 丘拉提斯股份有限公司 包含干扰素基因刺激蛋白激动剂的免疫佐剂及疫苗组合物
MA53659A (fr) 2018-09-21 2022-02-23 Shanghai De Novo Pharmatech Co Ltd Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
WO2020092127A1 (en) 2018-10-29 2020-05-07 Venenum Biodesign, LLC Novel sting agonists
WO2020092633A1 (en) 2018-10-30 2020-05-07 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
CN113348181A (zh) 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
KR102620495B1 (ko) * 2019-01-10 2024-01-04 셴젠 잉 바이오파마수티칼 씨오., 엘티디. 시클릭 디뉴클레오티드 프로드러그 분자 및 이의 제조 방법과 응용
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
EP3935066A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020191369A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2020191377A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
US12281109B2 (en) 2019-04-04 2025-04-22 Merck Sharp & Dohme Llc Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
SG11202112223XA (en) 2019-05-10 2021-12-30 Takeda Pharmaceuticals Co Antibody drug conjugates
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4007758A1 (en) 2019-08-02 2022-06-08 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
WO2021030251A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP3785719A1 (en) * 2019-08-28 2021-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH New use of cyclic dinucleotides
EP4034276A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
KR20220094221A (ko) 2019-09-25 2022-07-05 코디악 바이오사이언시즈, 인크. 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
MX2022003570A (es) 2019-09-25 2022-07-11 Codiak Biosciences Inc Composiciones de vesícula extracelular.
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
US20230074558A1 (en) 2019-12-06 2023-03-09 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
US12251449B2 (en) 2019-12-19 2025-03-18 William Marsh Rice University Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
WO2021126281A1 (en) 2019-12-20 2021-06-24 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
PH12022551961A1 (en) 2020-03-06 2023-10-09 Daiichi Sankyo Co Ltd Antibody-drug conjugate including novel cyclic dinucleotide derivative
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
EP4121450A2 (en) 2020-03-20 2023-01-25 Codiak BioSciences, Inc. Extracellular vesicles for therapy
MY210304A (en) 2020-04-02 2025-09-10 Mersana Therapeutics Inc Antibody drug conjugates comprising sting agonists
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
JP7776145B2 (ja) 2020-05-13 2025-11-26 マサチューセッツ インスティテュート オブ テクノロジー ポリマーマイクロデバイスの組成物およびがん免疫療法におけるその使用
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
WO2022050300A1 (ja) 2020-09-02 2022-03-10 第一三共株式会社 新規エンド－β－Ｎ－アセチルグルコサミニダーゼ
US20230366794A1 (en) 2020-09-23 2023-11-16 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
EP4216993A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
JP2023545178A (ja) 2020-10-14 2023-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ
JP2023546278A (ja) * 2020-10-20 2023-11-01 タイリガンド バイオサイエンス（シャンハイ）リミテッド 多機能環状ジヌクレオチド及びその使用
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
KR20230121800A (ko) 2020-12-17 2023-08-21 트러스티즈 오브 터프츠 칼리지 Fap-활성화된 래디오테라노스틱스, 및 이와 관련된용도
EP4032545A1 (en) * 2021-01-26 2022-07-27 Medizinische Hochschule Hannover Immunogenic composition and vaccine containing chlamydia ssp. surface antigens and its use
US20240423927A1 (en) 2021-04-20 2024-12-26 Institut Curie Compositions and methods for use in immunotherapy
EP4326321A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
CA3253428A1 (en) 2022-03-02 2025-06-16 Daiichi Sankyo Company, Limited PROCESS FOR PRODUCING A MOLECULE CONTAINING Fc
JP2025509191A (ja) 2022-03-04 2025-04-11 マサチューセッツ インスティテュート オブ テクノロジー 経粘膜性の両親媒性物質－タンパク質コンジュゲートワクチン
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
EP4569129A1 (en) * 2022-08-10 2025-06-18 Aldevron, LLC Methods for producing cyclic dinucleotides
CN115381936A (zh) * 2022-08-29 2022-11-25 福建师范大学 一种猴痘病毒疫苗
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
WO2024199359A1 (zh) * 2023-03-28 2024-10-03 江苏瑞科生物技术股份有限公司 包含环二核苷酸分子的脂质体佐剂系统及其制备方法
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof
CN116392585A (zh) * 2023-04-06 2023-07-07 中山大学孙逸仙纪念医院 一种肿瘤疫苗佐剂及其应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
GB2257704B (en) * 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
CA2318372C (en) 1998-02-02 2008-08-19 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
KR100455814B1 (ko) 1999-02-15 2004-11-06 니뽄 신야쿠 가부시키가이샤 단쇄화 폴리뉴클레오티드 및 그 제법
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
EP1320602A2 (en) 2000-09-21 2003-06-25 The Regents Of The University Of California Spas-1 cancer antigen
ES2295229T3 (es) 2000-10-18 2008-04-16 Glaxosmithkline Biologicals S.A. Vacunas contra canceres.
WO2002059575A2 (en) 2001-01-23 2002-08-01 The Trustees Of Princeton University, Princeton University Method and apparatus for analysis of biological solutions
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
AU2004275696B2 (en) 2003-07-28 2010-02-18 Karagen Pharmaceuticals, Inc. Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
KR20060123170A (ko) * 2003-10-24 2006-12-01 알자 코포레이션 지질 입자의 제조방법
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
JP4931798B2 (ja) * 2004-03-15 2012-05-16 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
US20060286549A1 (en) 2005-05-06 2006-12-21 The Regents Of The University Of California Microfluidic system for identifying or sizing individual particles passing through a channel
US20070059683A1 (en) 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
JP2009544754A (ja) * 2006-07-28 2009-12-17 アプライド バイオシステムズ， エルエルシー ジヌクレオチドｍｒｎａキャップアナログ
CA2662335A1 (en) 2006-09-05 2008-03-13 Valeria Ossovskaya Methods for designing parp inhibitors and uses thereof
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
PE20110998A1 (es) * 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
CA2754896C (en) 2009-03-09 2017-11-28 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
US8414630B2 (en) 2009-03-10 2013-04-09 Marc Evan Richelsoph Active bone screw
JP5830015B2 (ja) 2009-06-05 2015-12-09 インフェクシャス ディズィーズ リサーチ インスティチュート 合成グルコピラノシル脂質アジュバント
EP2448954A1 (en) 2009-07-01 2012-05-09 Rutgers, The State University of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US8771933B2 (en) 2009-10-06 2014-07-08 Massachusetts Institute Of Technology Continuous-flow deformability-based cell separation
CN102686729B (zh) * 2009-12-18 2015-09-23 箭头研究公司 用于治疗hsf1相关疾病的有机组合物
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
US20110293558A1 (en) 2010-03-22 2011-12-01 Massachusetts Institute Of Technology Material properties of t cells and related methods and compositions
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
ES2684684T3 (es) 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
US9061048B2 (en) 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
US8772474B2 (en) * 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
CA2833026A1 (en) 2011-04-15 2012-10-18 The University Of British Columbia Method and apparatus for separation of particles
WO2013086331A1 (en) 2011-12-07 2013-06-13 President And Fellows Of Harvard College High efficiency di-nucleotide cyclase
JP2015516989A (ja) 2012-04-30 2015-06-18 バーバー, グレン, エヌ.BARBER, Glen, N. 免疫反応の変調
SG11201407875UA (en) 2012-06-08 2014-12-30 Aduro Biotech Compostions and methods for cancer immunotherapy
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
SG10201704611WA (en) 2012-12-13 2017-07-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
PT2934598T (pt) 2012-12-19 2018-07-24 Univ Texas Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero
MX374828B (es) 2013-04-29 2025-03-06 Memorial Sloan Kettering Cancer Center Composiciones y metodos para alterar la señalizacion del segundo mensajero.
US20140329889A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
CN105188373B (zh) 2013-05-18 2017-09-22 艾杜罗生物科技公司 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
EP2996473B1 (en) 2013-05-18 2019-08-21 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP2016535731A (ja) 2013-10-21 2016-11-17 ドレクセル ユニバーシティ 慢性ｂ型肝炎ウイルス感染を処置するためのｓｔｉｎｇアゴニストの使用
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
WO2015085565A1 (en) 2013-12-13 2015-06-18 Qualcomm Incorporated Methods and apparatus for cell selection in a wireless communication system
WO2015108595A1 (en) 2014-01-15 2015-07-23 Nikolai Khodarev Anti-tumor therapy
AU2015270640B2 (en) 2014-06-04 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
US10011630B2 (en) 2014-12-16 2018-07-03 Invivogen Cyclic dinucleotides for cytokine induction
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6692826B2 (ja) * 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting

Also Published As

Publication number Publication date
BR112015013440B1 (pt) 2020-12-08
CA2886456A1 (en) 2014-06-19
US9695212B2 (en) 2017-07-04
ES2718910T3 (es) 2019-07-05
AU2018203682B2 (en) 2020-07-02
DK2931738T3 (en) 2019-04-15
AU2018203682A1 (en) 2018-06-14
HUE043262T2 (hu) 2019-08-28
EP2931738A4 (en) 2016-04-27
BR112015013440A2 (pt) 2017-07-11
PT2931738T (pt) 2019-04-10
MX2015007447A (es) 2015-12-09
HK1212707A1 (zh) 2016-06-17
EP2931738B1 (en) 2019-02-06
SG10201704611WA (en) 2017-07-28
US10414789B2 (en) 2019-09-17
PL2931738T3 (pl) 2019-07-31
EA201590396A1 (ru) 2015-12-30
AU2013358892B2 (en) 2018-06-21
NZ707561A (en) 2020-11-27
EP3527579A1 (en) 2019-08-21
EP2931738A1 (en) 2015-10-21
JP6333843B2 (ja) 2018-05-30
JP6704012B2 (ja) 2020-06-03
SI2931738T1 (sl) 2019-05-31
WO2014093936A1 (en) 2014-06-19
AU2013358892A1 (en) 2015-05-21
JP2016503029A (ja) 2016-02-01
KR20150095668A (ko) 2015-08-21
US20140205653A1 (en) 2014-07-24
JP2018135367A (ja) 2018-08-30
SG11201502796RA (en) 2015-05-28
US20170283454A1 (en) 2017-10-05
CN108542913A (zh) 2018-09-18
CN105008381B (zh) 2018-08-07
CN105008381A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
MX361680B (es) Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
MY175308A (en) Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
PH12017501506A1 (en) Compositions and methods for activating``stimulator of interferon gene`` -dependent signalling
MX2018005299A (es) Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon".
IN2014MN02492A (enExample)
MD20150091A2 (ro) Compuşi antivirali
MX2014008591A (es) Piperidinamidas piranoespirociclicas como moduladores de canales de iones.
MX2018007115A (es) Composiciones de blanqueamiento dental que comprenden un complejo de peroxido y sal de percarbonato.
MY173521A (en) Trpv4 antagonists
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
HK1208598A1 (en) Methods and compositions for treating pain
TN2015000408A1 (en) Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EA201592204A1 (ru) Композиции и способы для активации передачи сигналов, зависящей от "стимулятора гена интерферона"
PH12014500979A1 (en) Therapeutic combination of memantine and baclofen and pharmaceutical composition containing them
PL406423A1 (pl) Zawiesina do wytwarzania kompozycji stomatologicznych i sposób jej wytwarzania

Legal Events

Date Code Title Description
FG Grant or registration